

Table 1: Comparison between our current manuscript with previous literature dealing with the analysis of LND and DEX in biological fluids.


| Analytical method [Reference number] | Linearity range | LOD | LOQ | Application | Remarks |
|---|--|---------------|-----------|---|---|
| LND | | | | | |
| HPLC-UV | | | | | |
| [26] | 0.1-50 nM | 0.009 nM | 0.1 nM | Determination of LND in human plasma and cerebrospinal fluid | *SPE of the analyzed samples. *Total run time was 7 min. LND was eluted at 5.5 min. |
| HPLC-fluorimetry | | | | | |
| [27] | 5-100 ng/mL | 0.8 ng/mL | 2.3 ng/mL | Determination of LND in spiked plasma samples. | *Protein precipitation of the analyzed samples with acetonitrile followed by complexation of the endogenous amino acids with copper ions. *Precolumn derivatization with fluorescamine. *Total run time was 20 min. LND was eluted at 11.6 min. |
| HPLC-MS | | | | | |
| [28] | The same analytical method as reference [24] | | | Estimation of the maximum tolerated dose (MTD), describes toxicities, and evaluates pharmacokinetics. | *SPE of blood samples |
| [29] | 5-100 ng/mL | Not mentioned | 5 ng/mL | -Quantitation of LND in human plasma. -Application to a pharmacokinetic study in a single patient. | *LLE of the plasma samples with acetonitrile/1-chlorobutane (4:1, v/v). * Total run time was 8 min. LND was eluted at 3.2 min. |
| LC-MS/MS | | | | | |
| [30] | 2-1000 ng/mL | Not mentioned | 2 ng/mL | -Quantitation of LND in human plasma | *SPE of plasma samples. *Box-Behnken experimental design was applied for the validation of robustness. * Total run time was |

| | | | | | |
|-----------------------|-------------------|---------------|-------------|--|--|
| | | | | | 3 min. LND was eluted at 1.04 min. |
| [31] | 0.97-486.19 ng/mL | Not mentioned | 0.97 ng/mL | -Simultaneous quantitation of LND, idelalisib, and fudarabine in rat plasma. -Application to a pharmacokinetic study. | *LLE of plasma samples with t-butyl methyl ether. * Total run time was 4 min. LND was eluted at 3.0 min |
| [32] | 5-1000 ng/mL | Not mentioned | 5 ng/mL | -Assessment of the pharmacokinetics of [¹⁴ C] LND following oral administration in healthy human subjects. -Application to plasma, feces, urine, and semen samples. | * All samples required pH adjustment before analysis. *The use of radio-scintillation counter for measuring the radioactivity. * Total run time was 50 min. LND was eluted at 30.1 min |
| [33] | 1-1000 nM | Not mentioned | 1 nM | -Simultaneous quantitation of LND and flavopiridol in human plasma. | * LLE of plasma samples. * Total run time was 10 min. LND was eluted at 1.04 min. |
| UPLC-MS/MS | | | | | |
| [34] | 0.23-1000 ng/mL | Not mentioned | 0.23 ng/mL | -Determination of LND in spiked animal and human plasma samples. | *Protein precipitation of plasma samples with methanol. * Total run time was 3 min. LND was eluted at 0.70 min. |
| Current method | 0.01-0.5 ng/mL | 0.004 ng/mL | 0.01 ng/mL | -Determination of LND and DEX in plasma samples. -Determination of the pharmacokinetics of LND either alone or in combination with LND following oral administration to rats. | *SPE of the analyzed sample. * Total run time was 1.5 min. LND was eluted at 0.36 min. |
| DEX | | | | | |
| HPLC-UV | | | | | |
| [35] | 0.702-70.2 ng/mL | Not mentioned | 0.702 ng/mL | -Evaluation of the pharmacodynamics, pharmacokinetics, and comparative bioavailability of a commercial oral | *LLE of plasma samples with diethylether. * Total run time was 25.5 min. |


| | | | | | |
|-----------------|---------------|---------------|-----------|--|---|
| | | | | DEX formulation intended for pediatric use relative to those in tablets. -Determination of DEX in human plasma. | |
| LC-MS | | | | | |
| [36] | 6-100 ng/mL | 1 ng/mL | 6 ng/mL | -Determination of DEX in sheep plasma. -Application to a pharmacokinetic study. | * SPE of plasma samples. *Total run time was 9 min. DEX was eluted at 5.83 min. |
| [37] | 4.5-450 pmol | 1 pmol | 4.5 pmol | -Quantitation of DEX in blood samples. | *LLE of plasma samples with diethylether. *Total run time was 10 min. DEX was eluted at 5.0 min. |
| LC-MS/MS | | | | | |
| [38] | 2.5-250 ng/mL | 0.6 ng/mL | 2.5 ng/mL | -Simultaneous determination of DEX and DEX palmitate in human plasma. -Application to a pharmacokinetic study following IV injection to human volunteers. | *LLE of plasma samples with diethylether : dichloromethane (60:40, v/v). * Total run time was 6 min. DEX was eluted at 4.2 min. |
| [39] | 0.5-500 µg/L | Not mentioned | 0.5 µg/L | -Determination of DEX and DEX sodium palmitate in plasma and human cochlear perilymph. -Application to a pharmacokinetic study. | *Protein precipitation of the analyzed samples with methanol/acetonitrile (1: 4, v/v). * Total run time was 5 min. DEX was eluted at 2.79 min. |
| [40] | 2-1000 ng/mL | 0.01 ng/mL | 2 ng/mL | -Determination of the pharmacokinetics of DEX in broiler chicken. -Quantitation of DEX in plasma samples. | *Protein precipitation of the analyzed samples with 20% trichloroacetic acid followed by LLE with diethyl ether. *Total run time was 6 min. |
| UPLC-MS | | | | | |
| [41] | 1-5 µg/L | 0.1 µg/L | 0.6 µg/L | -Multidetecion of corticosteroids in sports doping and | *LLE of the analyzed samples with diethylether. |

| | | | | | |
|--------------------------|----------------|---------------|------------|--|---|
| | | | | veterinary control. -Multiresidue analysis of corticosteroids in human and veterinary urine. | *Total run time was 7.5 min. DEX was eluted at 3.6 min. |
| <i>UPLC-MS/MS</i> | | | | | |
| [42] | 5-500nmol/L | Not mentioned | 1 nmol/L | -Determination of corticosteroid mixtures in plasma, urine, and saliva. | *SPE of the analyzed sample. * Total run time was 3 min. DEX was eluted at 2.02 min. |
| Current method | 0.01-0.5 ng/mL | 0.004 ng/mL | 0.01 ng/mL | -Determination of LND and DEX in plasma samples. -Determination of the pharmacokinetics of DEX either alone or in combination with LND following oral administration to rats. | *SPE of the analyzed sample. * Total run time was 1.5 min. DEX was eluted at 0.36 min. |


a)




b)




c)



d)



e)



f)






Fig. 1 TIC and MRM chromatograms of standard mixtures of DEX, LND, and OND (IS) showing the effect of acetonitrile% in the mobile phase, 30%, a), 40%, b), 50%, c), 60%, d), 70%, e), and 80%, f). All mobile phases were composed of mixtures of water and acetonitrile in different ratios, all with 0.1% formic acid.


a)



b)



c)



d)




Fig. 2 TIC and MRM chromatograms of standard mixtures of DEX, LND, and OND (IS) showing the effect of formic acid% in the mobile phase, 0.01%, a), 0.05%, b), 0.1%, c), and 0.15%, d). All mobile phases were composed of mixtures of water and 80% acetonitrile with different percentage of formic acid.